Erlonat 150mg Tablet

About

Erlonat 150mg Tablet is a targeted therapy medication, specifically a tyrosine kinase inhibitor (TKI), used in the treatment of certain cancers. It works by selectively inhibiting the epidermal growth factor receptor (EGFR) tyrosine kinase, which plays a crucial role in the growth and proliferation of cancer cells. By blocking the signaling pathways mediated by EGFR, Erlonat helps to slow down or stop the growth of tumors. This medication is particularly effective in patients with non-small cell lung cancer (NSCLC) that harbor specific EGFR mutations, and it is also used in combination with other therapies for pancreatic cancer. Its targeted mechanism offers a more precise approach to cancer treatment compared to traditional chemotherapy, often leading to improved outcomes in selected patient populations.

Uses

• Non-small cell lung cancer (NSCLC) with EGFR mutations
• Maintenance therapy for advanced NSCLC
• Pancreatic cancer (in combination with gemcitabine)
• Advanced solid tumors (off-label use in specific cases)

Directions For Use

Take on an empty stomach, at least one hour before or two hours after food. Follow your doctor's dosing schedule precisely.

Benefits

• Targets specific cancer cell growth pathways
• Effective in EGFR mutation-positive NSCLC
• Can improve progression-free survival in certain cancers
• Offers an oral administration route for convenience
• May extend overall survival in selected patients
• Potentially fewer systemic side effects than traditional chemotherapy

Side Effects

• Rash (acneiform)
• Diarrhea
• Nausea
• Vomiting
• Fatigue
• Anorexia
• Dry skin
• Pruritus
• Stomatitis
• Conjunctivitis
• Interstitial lung disease (rare but serious)
• Liver dysfunction

Safety Measures

• Alcohol - Avoid alcohol consumption, as it may exacerbate liver-related side effects and should be discussed with your doctor.
• Pregnancy - Avoid during pregnancy. It has teratogenic potential; women of childbearing potential must use effective contraception during treatment and for at least 2 weeks after the last dose.
• Breastfeeding - Avoid during breastfeeding. It is unknown if Erlonat is excreted in human milk, but due to the potential for serious adverse effects in the infant, breastfeeding is not recommended.
• Liver - Use with caution in patients with liver impairment. Monitor liver function tests regularly, and dose adjustment may be necessary.
• Kidney - Use with caution in patients with kidney conditions. No specific dose adjustment guidelines are available, but close monitoring is advised.
• Lung - Use with extreme caution. There is a risk of interstitial lung disease (ILD); monitor for new or worsening respiratory symptoms like cough, dyspnea, or fever.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.